lbh581
Small moleculeexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2008 (NCT01222936)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Histone deacetylase 2INHIBITOR
HDAC2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- lbh581
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01222936 | Phase 2 | May 1, 2008 | Azienda Ospedaliera San Camillo Forlanini, Novartis, Southern Europe New Drug Organization (SENDO) |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Azienda Ospedaliera San Camillo Forlanini | Academic/Hospital | 1 | 0 | 1 | 2008 |
| Novartis | For profit | 1 | 0 | 1 | 2008 |
| Southern Europe New Drug Organization (SENDO) | Academic/Hospital | 1 | 1 | 1 | 2008 |
3 organizations
Page 1 / 1